We are live on ! Find out more
BC

Broadfin Capital Portfolio holdings

AUM $747M
1-Year Est. Return 100.56%
This Fund
S&P 500
This Quarter Est. Return
+18.31%
1 Year Est. Return
+100.56%
3 Year Est. Return
+297.65%
5 Year Est. Return
+365.91%
10 Year Est. Return
–
AUM
$635M
AUM Growth
-$6.52M
Cap. Flow
-$38.5M
Cap. Flow %
-6.06%
Top 10 Hldgs %
52.93%
Holding
70
New
19
Increased
8
Reduced
12
Closed
25

Top Buys

Rank Stock Value
1
IOVA icon
Iovance Biotherapeutics
IOVA
+$47.3M
2
ENDP
Endo International plc
ENDP
+$17.4M
3
EXAS
Exact Sciences
EXAS
+$14.1M
4
ADMA icon
ADMA Biologics
ADMA
+$12.6M
5
XRAY icon
Dentsply Sirona
XRAY
+$12.3M

Top Sells

Rank Stock Value
1
HRTX icon
Heron Therapeutics
HRTX
+$33.8M
2
GWPH
GW Pharmaceuticals Plc American Depositary Shares
GWPH
+$19.7M
3
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$18.7M
4
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$16M
5
ANGO icon
AngioDynamics
ANGO
+$15.7M

Sector Composition

Rank Sector Weight
1 Healthcare 84.19%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
KALA icon
26
KALA BIO
KALA
$11.9M
$8.22M 1.29%
240
-33
-12% -$1.27M
LIVN icon
27
LivaNova
LIVN
$4.29B
$7.2M 1.13%
+72,100
New +$6.55M
NVLN
28
DELISTED
Novelion Therapeutics Inc. Common Shares
NVLN
$7.17M 1.13%
1,948,554
– –
MTD icon
29
Mettler-Toledo International
MTD
$26.8B
$6.89M 1.08%
+11,900
New +$6.79M
SRRA
30
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
$6.24M 0.98%
+52,665
New +$5.28M
SSKN
31
DELISTED
Strata Skin Sciences
SSKN
$6.04M 0.95%
294,382
+274,047
+1,348% +$4.47M
TSRO
32
CALL
DELISTED
TESARO, Inc.
TSRO
$5.56M 0.88%
+125,000
New +$6.07M
SLGL icon
33
Sol-Gel Technologies
SLGL
$264M
$5M 0.79%
64,770
– –
XERS icon
34
Xeris Biopharma Holdings
XERS
$1.44B
$4.75M 0.75%
+250,000
New +$4.86M
AMRN
35
CALL
Amarin Corp
AMRN
$285M
$4.5M 0.71%
+72,750
New +$4.51M
HRTX icon
36
CALL
Heron Therapeutics
HRTX
$85.8M
$3.88M 0.61%
+100,000
New +$3.18M
PACB icon
37
Pacific Biosciences
PACB
$419M
$3.74M 0.59%
+1,054,091
New +$2.92M
GBT
38
DELISTED
Global Blood Therapeutics, Inc.
GBT
$3.62M 0.57%
+80,100
New +$3.65M
QTNT
39
DELISTED
Quotient Limited Ordinary Shares
QTNT
$3.53M 0.56%
+10,993
New +$2.57M
ATEC icon
40
Alphatec Holdings
ATEC
$1.27B
$3.31M 0.52%
+1,111,112
New +$3.94M
MDWD icon
41
MediWound
MDWD
$181M
$3.29M 0.52%
68,157
-3,272
-5% -$141K
SCYX icon
42
SCYNEXIS
SCYX
$37.6M
$3.09M 0.49%
23,574
– –
ODT
43
DELISTED
Odonate Therapeutics, Inc. Common Stock
ODT
$2.06M 0.32%
+93,081
New +$2.17M
IOVA icon
44
CALL
Iovance Biotherapeutics
IOVA
$2.24B
$352K 0.06%
+27,500
New +$402K
AMRN
45
Amarin Corp
AMRN
$285M
– –
-103,940
Closed -$6.44M
ANAB icon
46
AnaptysBio
ANAB
$1.59B
– –
-79,200
Closed -$8.24M
ANGO icon
47
AngioDynamics
ANGO
$560M
– –
-911,707
Closed -$15.7M
CDTX
48
DELISTED
Cidara Therapeutics
CDTX
– –
-18,791
Closed -$1.5M
CI icon
49
Cigna
CI
$76.5B
– –
-42,600
Closed -$7.15M
ESPR
50
DELISTED
Esperion Therapeutics
ESPR
– –
-86,786
Closed -$6.28M
1
2
3

Similar funds

CBU
CIBC Bank USA Chicago, Illinois $756M AUM 24.68% 1-Year Est. Return
CONA
Capital One National Association New York $756M AUM
MP
Manikay Partners New York $893M AUM 55.39% 1-Year Est. Return
SC
Selz Capital New York $570M AUM 35.56% 1-Year Est. Return
KGACF
Kopernik Global All-Cap Fund Tampa, Florida $558M AUM
BPWA
Beacon Pointe Wealth Advisors Newport Beach, California $543M AUM 23.61% 1-Year Est. Return
TRAM
Tuscan Ridge Asset Management Chicago, Illinois $984M AUM 25.8% 1-Year Est. Return
VMI
VHCP Management III New York $504M AUM 683.12% 1-Year Est. Return

Broadfin Capital's Q2 2018 Portfolio in Review

As of Q2 2018, Broadfin Capital held 70 positions worth $635M, down 1% from $642M the previous quarter. Its ten largest holdings account for 53% of the portfolio.

Broadfin Capital withdrew a net $38.5M in Q2 2018, closing 25 positions and reducing 12 holdings. Its most notable exit was GW Pharmaceuticals Plc American Depositary Shares, an estimated $19.7M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 84% of assets, down from 87% a quarter earlier.

Against the trend, Broadfin Capital opened a new position in Endo International plc worth $24.4M.

  • Broadfin Capital's largest Q2 2018 buy was Endo International plc: 2,591,573 shares worth $24.4M.
  • Broadfin Capital added most to Iovance Biotherapeutics in Q2 2018, an estimated $47.3M increase.
  • Broadfin Capital's biggest Q2 2018 reduction was Heron Therapeutics, cutting an estimated $33.8M.
  • Broadfin Capital fully exited GW Pharmaceuticals Plc American Depositary Shares in Q2 2018, selling an estimated $19.7M.
  • Broadfin Capital's ten largest holdings make up 53% of its $635M portfolio in Q2 2018.
  • Broadfin Capital opened 19 new positions and closed 25 in Q2 2018.
  • Broadfin Capital's portfolio value fell 1% quarter-over-quarter to $635M.

Based on Broadfin Capital's 13F filing for Q2 2018, filed 14 Aug 2018.